Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 4
1969 2
1974 2
1975 1
1976 1
1979 2
1980 2
1982 1
1983 4
1986 2
1987 3
1988 1
1989 3
1990 4
1991 2
1992 3
1993 5
1994 4
1995 8
1996 7
1997 5
1998 4
1999 9
2001 2
2002 1
2003 3
2004 1
2005 5
2006 2
2007 1
2008 2
2010 3
2011 5
2012 1
2013 5
2014 2
2015 4
2016 6
2017 4
2018 15
2019 5
2020 5
2021 1
2022 3
2023 3
2024 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Results by year

Filters applied: . Clear all
Page 1
The effects of topical oxymetazoline on eyelid position, eye redness, and patient-reported eye appearance: A randomized controlled trial.
Shoji MK, Markatia Z, Ameli K, Bayaraa M, Clauss KD, Ugradar S, Lee WW. Shoji MK, et al. J Plast Reconstr Aesthet Surg. 2023 May;80:66-74. doi: 10.1016/j.bjps.2023.02.006. Epub 2023 Feb 9. J Plast Reconstr Aesthet Surg. 2023. PMID: 36996503 Free article. Clinical Trial.
PURPOSE: This study assesses the effects of topical oxymetazoline 0.1% on eyelid position, eye redness, and patient-perceived eye appearance in patients without severe ptosis. ...Patients aged 18-100 years were randomized to receive one drop of oxymetazoline hydroch …
PURPOSE: This study assesses the effects of topical oxymetazoline 0.1% on eyelid position, eye redness, and patient-perceived eye app …
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial.
Baumann L, Goldberg DJ, Stein Gold L, Tanghetti EA, Lain E, Kaufman J, Weng E, Berk DR, Ahluwalia G. Baumann L, et al. J Drugs Dermatol. 2018 Mar 1;17(3):290-298. J Drugs Dermatol. 2018. PMID: 29537447 Clinical Trial.
The proportion of patients achieving the primary efficacy outcome was significantly greater with oxymetazoline versus vehicle (P=0.001). Similar results favoring oxymetazoline over vehicle were observed for the individual CEA and SSA scores (P less than 0.001 and P= …
The proportion of patients achieving the primary efficacy outcome was significantly greater with oxymetazoline versus vehicle (P=0.00 …
Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1.0% for persistent erythema of rosacea in a phase IV study.
Eichenfield LF, Del Rosso JQ, Tan JKL, Hebert AA, Webster GF, Harper J, Baldwin HE, Kircik LH, Stein-Gold L, Kaoukhov A, Alvandi N. Eichenfield LF, et al. Br J Dermatol. 2019 May;180(5):1050-1057. doi: 10.1111/bjd.17462. Epub 2019 Feb 27. Br J Dermatol. 2019. PMID: 30500065 Free PMC article. Clinical Trial.
BACKGROUND: Once-daily topical oxymetazoline cream 1.0% significantly reduced persistent facial erythema of rosacea in trials requiring live, static patient assessments. ...RESULTS: Among 835 patients (oxymetazoline n = 415, vehicle n = 420), significantly greater p …
BACKGROUND: Once-daily topical oxymetazoline cream 1.0% significantly reduced persistent facial erythema of rosacea in trials requiri …
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial.
Kircik LH, DuBois J, Draelos ZD, Werschler P, Grande K, Cook-Bolden FE, Weng E, Berk DR, Ahluwalia G. Kircik LH, et al. J Drugs Dermatol. 2018 Jan 1;17(1):97-105. J Drugs Dermatol. 2018. PMID: 29320594 Clinical Trial.
The incidence of discontinuation due to TEAEs was low in both groups (oxymetazoline group, 1.8%; vehicle group, 0.5%). The most common TEAEs reported during the entire study period were application-site dermatitis, application-site erythema, and headache in the oxymetaz …
The incidence of discontinuation due to TEAEs was low in both groups (oxymetazoline group, 1.8%; vehicle group, 0.5%). The most commo …
Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial.
Guzman CB, Dulude H, Piché C, Rufiange M, Sadoune AA, Rampakakis E, Carballo D, Triest M, Zhang MX, Zhang S, Tafreshi M, Sicard E. Guzman CB, et al. Diabetes Obes Metab. 2018 Mar;20(3):646-653. doi: 10.1111/dom.13134. Epub 2017 Nov 19. Diabetes Obes Metab. 2018. PMID: 29053231 Free PMC article. Clinical Trial.
Cohort 2 participants (N = 18), who also had colds with nasal congestion, received a single dose of NG 2 hours after treatment with the decongestant oxymetazoline. Total symptoms score and other safety measures were assessed before and after NG administration. ...
Cohort 2 participants (N = 18), who also had colds with nasal congestion, received a single dose of NG 2 hours after treatment with the deco …
A clinical comparison of budesonide nasal aerosol, terfenadine and a combined therapy of budesonide and oxymetazoline in adult patients with perennial rhinitis.
Lau SK, Wei WI, Van Hasselt CA, Sham CL, Woo J, Choa D, Engzell UC. Lau SK, et al. Asian Pac J Allergy Immunol. 1990 Dec;8(2):109-15. Asian Pac J Allergy Immunol. 1990. PMID: 1709020 Free article. Clinical Trial.
The efficacy of budesonide, terfenadine and a combination of budesonide and oxymetazoline in the treatment of perennial rhinitis was evaluated by a double blind, parallel group study. ...Budesonide with oxymetazoline for the first three days showed a faster relief o …
The efficacy of budesonide, terfenadine and a combination of budesonide and oxymetazoline in the treatment of perennial rhinitis was …
A Randomized Controlled Pilot Study: Combined 595-nm Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride Topical Cream Superior to Oxymetazoline Hydrochloride Cream for Erythematotelangiectatic Rosacea.
Sodha P, Suggs A, Munavalli GS, Friedman PM. Sodha P, et al. Lasers Surg Med. 2021 Dec;53(10):1307-1315. doi: 10.1002/lsm.23439. Epub 2021 Jul 7. Lasers Surg Med. 2021. PMID: 34233378 Free PMC article. Clinical Trial.
BACKGROUND AND OBJECTIVES: We evaluated if oxymetazoline therapy combined with 595-nm pulsed dye laser (PDL) will be more beneficial than topical oxymetazoline alone for the improvement of erythematotelangiectatic rosacea. STUDY DESIGN/MATERIALS AND METHODS: This wa …
BACKGROUND AND OBJECTIVES: We evaluated if oxymetazoline therapy combined with 595-nm pulsed dye laser (PDL) will be more beneficial …
Combination of mometasone furoate and oxymetazoline for the treatment of adenoid hypertrophy concomitant with allergic rhinitis: A randomized controlled trial.
Liu W, Zhou L, Zeng Q, Luo R. Liu W, et al. Sci Rep. 2017 Jan 18;7:40425. doi: 10.1038/srep40425. Sci Rep. 2017. PMID: 28098165 Free PMC article. Clinical Trial.
To determine whether the combination of mometasone furoate (MF) and oxymetazoline (OXY) is more effective than either agent alone, we performed a two-stage, parallel, randomized, double-blind, double-dummy, clinical trial with 240 AH children with concomitant perennial AR. …
To determine whether the combination of mometasone furoate (MF) and oxymetazoline (OXY) is more effective than either agent alone, we …
Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment.
Zannikos P, Solanki B, De Meulder M, Badorrek P, Hohlfeld JM, Singh J. Zannikos P, et al. Clin Pharmacokinet. 2023 Sep;62(9):1315-1328. doi: 10.1007/s40262-023-01273-z. Epub 2023 Jul 4. Clin Pharmacokinet. 2023. PMID: 37402024 Clinical Trial.
METHODS: Patients with allergic rhinitis self-administered 56 mg of nasal esketamine after pretreatment with nasal oxymetazoline (0.05%) at 1 h before esketamine and without oxymetazoline pretreatment. They were exposed to grass pollen in an allergen challenge chamb …
METHODS: Patients with allergic rhinitis self-administered 56 mg of nasal esketamine after pretreatment with nasal oxymetazoline (0.0 …
151 results